Best-selling antidepressant drugs may be making some men infertile, according to research reported. The warning follows a study of two men at Cornell Medical Centre in New York whose sperm counts dropped dramatically to almost zero while taking the drugs, but recovered to healthy levels whenever their medication was suspended.
The Food and Drug Administration (FDA) announced the approval of Omnaris (ciclesonide) nasal spray, a new drug for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis, commonly known as hay fever, in adults and children 12 years of age and older.
Royal Philips (NYSE: PHG, AEX: PHI) will showcase innovative cardiac solutions designed to streamline workflow and facilitate advanced information management at Cardiovascular Research Foundation?s (CRF) eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.Shown for the first time ever in the U.S., the pre-release of the Philips Xcelera 2.1 Cardiovascular Information Solution is one of the key components to Philips integrated catheterization (cath) lab, which includes physiomonitoring, reporting and cardiovascular X-ray technologies to improve patient care and lab management.
Malignancies of the breast can be more aggressive and associated with poorer outcome in African-Americans than other races, according to a new study. Published in the December 1, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study reviewed patient data from two different clinical trial protocols – to control for healthcare access biases – and found that African-Americans have tumors with poorer prognostic cellular characteristics and more aggressive clinical presentations, pointing to the possibility that racially influenced tumor biology may contribute to observed racial disparities in breast cancer outcome.
A person suffering from tennis elbow may not have to look any further than his or her own body for the most effective treatment, according to a study published in the November issue of The American Journal of Sports Medicine. Specially prepared platelets taken from the patient which are then re-injected into the tendon of the affected elbow provides more relief than more commonly-used therapies which have failed to yield results, often resulting in surgery, concludes study authors Allan Mishra MD and Terri Pavelko, PAC, PT, of the Menlo Medical Clinic, Stanford University Medical Center, Menlo Park, Calif.
While some breast cancer survivors could benefit from adding aromatase inhibitors to the standard five years of tamoxifen, a new study shows the additional therapy should be weighed carefully for each individual. Writing in the December 1, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study’s authors say potential improvement in cancer-free survival beyond 5 years with the added therapy may be less than 2 percent for most patients.
To test the null hypothesis that, after 28 weeks of gestation, uterine blood flow during supine rest and supine exercise is no different than uterine blood flow at left-lateral rest, RM Jeffreys,a W Stepanchak,a B Lopez,a,b J Hardis,a JF Clapp IIIa,b,c conducted study in pregnant women at Department of Obstetrics, MetroHealth Medical Center, Cleveland, OH, USA.
The rising demand and increasing scarcity of donor oocytes in developed countries have led to some fertility clinics sourcing oocyte donors from abroad, particularly from poorer countries, in what is referred to as ‘transnational’ or ‘international’ oocyte donation. In a further new ‘twist’ to this scheme, frozen sperm of the recipient’s male partner is exported abroad through courier mail and is used to fertilise donor oocytes in a foreign clinic to produce embryos, which are then cryopreserved and imported back by mail for transfer to the woman.
Health Canada announced that it will grant licences with conditions to Inamed Corporation and Mentor Medical Systems to market their silicone gel-filled breast implants in Canada. These Class IV licences are conditional on the manufacturers meeting several requirements to ensure their devices continue to meet the safety and effectiveness requirements of the Medical Devices Regulations.
In another important milestone, Glivec? (imatinib) has received US regulatory approval to help patients with five distinct and potentially life-threatening disorders, representing the first time that a regulatory authority has ever simultaneously approved one targeted medicine for so many disorders. With today’s decision, and in only five years, Glivec has now been approved in the US for seven diseases, including two solid tumors and five blood disorders with molecular targets known to be inhibited by the drug.